The latest news releases from Fresenius Medical Care North America
For media inquiries, please contact media@fmc-na.com or 781-699-5280
Fresenius Medical Care, the world’s largest provider of dialysis products and services, today released the following statement in response to the defeat of the ballot initiative Proposition 8 in California.
Fresenius Medical Care’s Renal Therapies Group today announced the results of four studies utilizing the Crit-Line® monitor that examine how relative blood volume monitoring (RBV-M) can help improve patient outcomes. All four abstracts were accepted for poster presentation at the 2018 American Society of Nephrology’s (ASN) Kidney Week Symposium in San Diego, Calif.
Fresenius Medical Care North America (FMCNA), the nation’s leading renal care company, today announced the presentation of 71 abstracts at the 2018 American Society of Nephrology’s (ASN) Kidney Week Symposium. The company’s clinical experts demonstrate multiple advances in kidney care that improve patient outcomes, especially around artificial intelligence and connected home therapies.
Fresenius Kidney Care, the dialysis division of Fresenius Medical Care North America and the nation’s leading network of dialysis facilities, continues to provide care for dialysis patients in areas affected by Hurricane Florence. These patients, who require life-sustaining dialysis treatment every two to three days to stay healthy, are among the most vulnerable during a disaster. Patients have already been contacted by Fresenius Kidney Care with information on when and where to seek treatment before, during and after the storm.
Fresenius Medical Care North America (FMCNA), the nation’s leading renal care company, is making a $100,000 contribution to the American Nephrology Nurses Association (ANNA), a professional nursing organization with more than 8,500 members. In recognition of the organization’s 50th Anniversary year and Nephrology Nurses Week, the donation will fund an ongoing scholarship program, help increase awareness of the profession and strengthen engagement with nurses dedicated to caring for patients with chronic kidney disease.
Frenova Renal Research, a division of Fresenius Medical Care North America (FMCNA) and the world’s only contract clinical research services provider dedicated exclusively to renal research, today announces the addition of a fifth clinical research site to its Site Management Organization (SMO).
Fresenius Medical Care, the world’s largest provider of dialysis products and services, today announced the closing of the divestiture of Sound Inpatient Physicians Holdings, LLC (Sound) to an investment consortium led by Summit Partners as of June 28, 2018. The total transaction proceeds are $2.15 billion (EUR 1.85 billion1).
Fresenius Medical Care North America (FMCNA), the leading provider of kidney care products and services, today announced the publication of its 2018 Annual Medical Report, offering expert insights on the latest science and innovation that is transforming clinical practice and patient care. Entitled "Go Further, Faster: Translating Science Into Practice," this year's report features insights from more than two dozen FMCNA and Fresenius Medical Care leaders, researchers, scientists, mathematicians and caregivers from across the enterprise.
Fresenius Medical Care, the world’s largest provider of dialysis products and services, and Humacyte, Inc., a medical research, discovery and development company, today announced a strategic, global partnership and a $150M USD equity investment. This agreement has the potential to make Humacyte’s investigational human acellular vessel, HUMACYL®, available to more patients worldwide following approval of the product.
Fresenius Kidney Care, a division of Fresenius Medical Care North America and the nation’s leading network of dialysis facilities, announced today that it has achieved the highest results in the industry as part of the government’s Five-Star Quality Rating System. In the newly released government data, Fresenius Kidney Care is the clear leader, achieving the highest percentage of four and five star rated clinics when compared to all other major dialysis providers in the country.
Fresenius Medical Care North America (FMCNA), the leading provider of kidney care products and services, today announced the launch of the Fresenius Medical Care Foundation, a nonprofit created to address the environmental, social and economic conditions that increase the risk for chronic kidney disease (CKD).
Fresenius Medical Care, the world’s largest provider of dialysis products and services, today announced an important strategic step to sharpen its U.S. Care Coordination profile with the signing of a definitive agreement to divest its controlling interest in Sound Inpatient Physicians Holdings, LLC (Sound) to an investment consortium led by Summit Partners (Summit), for total transaction proceeds of $2.15 billion (EUR 1.76 billion).